ES2073751T3 - Nuevo peptido con actividad fisiologica de origen porcino. - Google Patents

Nuevo peptido con actividad fisiologica de origen porcino.

Info

Publication number
ES2073751T3
ES2073751T3 ES91908466T ES91908466T ES2073751T3 ES 2073751 T3 ES2073751 T3 ES 2073751T3 ES 91908466 T ES91908466 T ES 91908466T ES 91908466 T ES91908466 T ES 91908466T ES 2073751 T3 ES2073751 T3 ES 2073751T3
Authority
ES
Spain
Prior art keywords
edema
terminals
physiological activity
activities
new peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91908466T
Other languages
English (en)
Inventor
Hisayuki Matsuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2073751T3 publication Critical patent/ES2073751T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTA UN NUEVO PEPTIDO REPRESENTADO POR LA FORMULA ESTRUCTURA (I) Y UNA SAL DE ADICCION ACIDA DEL MISMO EN LA QUE LOS TERMINALES 1 Y 2 ESTAN DIRECTAMENTE UNIDOS UNO A OTRO Y POR LO TANTO CONSTITUYEN LOS TERMINALES 3 Y 4, Y LOS RESIDUOS DE CISTEINA (CIS) EN LAS POSICIONES 6INTRAMOLECULAR. DESDE EL MOMENTO QUE EL PEPTIDO PRESENTA ACTIVIDADES NATRIURETICAS E HIPOTENSORAS, ES UTIL PARA EL TRATAMIENTO DEL EDEMA CARDIACO, EL EDEMA RENAL, EL EDEMA HEPATICO, LA HIPERTENSION, EL FALLO CONGESTIVO, Y LA INSUFICIENCIA RENAL AGUDA Y CRONICA. COMO TAMBIEN PRESENTA ACTIVIDADES DE INHIBICION DEL CRECIMIENTO DE LAS CELULAS DEL MUSCULO VASCULAR Y PRODUCE CGMP, SE ESPERA QUE SEA BENEFICIOSO CONTRA LA ARTERIOSCLEROSIS.
ES91908466T 1990-04-20 1991-04-20 Nuevo peptido con actividad fisiologica de origen porcino. Expired - Lifetime ES2073751T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10504790 1990-04-20

Publications (1)

Publication Number Publication Date
ES2073751T3 true ES2073751T3 (es) 1995-08-16

Family

ID=14397086

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91908466T Expired - Lifetime ES2073751T3 (es) 1990-04-20 1991-04-20 Nuevo peptido con actividad fisiologica de origen porcino.

Country Status (9)

Country Link
US (1) US5352770A (es)
EP (1) EP0478797B1 (es)
JP (1) JP2636500B2 (es)
AT (1) ATE121102T1 (es)
DE (1) DE69108830T2 (es)
DK (1) DK0478797T3 (es)
ES (1) ES2073751T3 (es)
GR (1) GR3015762T3 (es)
WO (1) WO1991016342A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2809533B2 (ja) * 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
BRPI0203172B8 (pt) 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US7488713B2 (en) * 2004-03-18 2009-02-10 University Of South Florida Cancer treatment using C-type natriuretic peptides
US8759317B2 (en) * 2004-03-18 2014-06-24 University Of South Florida Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)
WO2005094889A1 (ja) 2004-03-31 2005-10-13 Chugai Seiyaku Kabushiki Kaisha 関節炎症治療剤又は予防剤
WO2005094890A1 (ja) 2004-03-31 2005-10-13 Kazuwa Nakao 身長増加用組成物
ES2687786T3 (es) 2004-04-21 2018-10-29 Alexion Pharmaceuticals, Inc. Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
EP2023950B1 (en) * 2006-05-05 2012-07-11 University of South Florida Urodilatin cancer treatment
CL2008003476A1 (es) * 2007-11-21 2009-08-14 Biomarin Pharm Inc Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
ES2904360T3 (es) 2009-05-20 2022-04-04 Biomarin Pharm Inc Variantes de péptido natriurético de tipo C
EP2658979B1 (en) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
SG11201401605QA (en) 2011-10-19 2014-09-26 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
ITRM20120060A1 (it) * 2012-02-21 2013-08-22 Consiglio Nazionale Ricerche Peptidi in grado di dissociare lo eterodimero mdm2/mdm4 e loro uso nel trattamento del cancro.
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
US10449236B2 (en) 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
RU2728567C2 (ru) 2015-07-30 2020-07-30 Байомарин Фармасьютикал Инк. Применение вариантов натрийуретического пептида с-типа для лечения скелетной дисплазии
RU2745528C2 (ru) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Производство щелочных фосфатаз
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
EP3368062A4 (en) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
MX2019011508A (es) 2017-03-31 2019-11-01 Alexion Pharma Inc Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes.
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
JP2022547723A (ja) 2019-09-16 2022-11-15 バイオマリン ファーマシューティカル インコーポレイテッド Ｃｎｐバリアントおよびそのコンジュゲート
US20230140311A1 (en) 2021-07-09 2023-05-04 Biomarin Pharmaceutical Inc. C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia in Children
WO2023108005A1 (en) 2021-12-07 2023-06-15 Biomarin Pharmaceutical Inc. C-type natriuretic peptide therapy of bone-related disorders
US20240209028A1 (en) 2022-11-02 2024-06-27 Novo Nordisk A/S Cnp compounds

Also Published As

Publication number Publication date
US5352770A (en) 1994-10-04
GR3015762T3 (en) 1995-07-31
DE69108830T2 (de) 1995-09-14
DE69108830D1 (de) 1995-05-18
DK0478797T3 (da) 1995-06-26
JP2636500B2 (ja) 1997-07-30
EP0478797A1 (en) 1992-04-08
ATE121102T1 (de) 1995-04-15
EP0478797A4 (en) 1993-09-01
WO1991016342A1 (en) 1991-10-31
EP0478797B1 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
ES2073751T3 (es) Nuevo peptido con actividad fisiologica de origen porcino.
ATE214940T1 (de) Verbesserte interferon-polymerkonjugate
RU94018226A (ru) Метансульфонат (е)-3-/2-н-бутил-1-//4-карбоксифенил/метил/-1н-имидазол-5-ил/-2-/2-тиенил/метил-2-пропеновой кислоты, способ его получения, фармацевтическая композиция на его основе
DK0415456T3 (da) Xanthinforbindelser
AU622022B2 (en) Salts of azelastine having improved solubility
FI906296A0 (fi) Nya metylenbisfosfonsyrederivat.
TW200510369A (en) Novel ethylenediamine derivatives
DE3783579D1 (de) Derivate des alpha-anp und ihre herstellung.
EP0159040A3 (en) Pyridine derivatives and production thereof
FI943808A (fi) Triatsolopyrimidiinijohdannaisia angiotensiini II:n reseptoreiden vastavaikuttajina
EA199800035A1 (ru) Способ получения производных дифенила и промежуточное для получения дифенила
ES8603724A1 (es) Procedimiento de preparacion de nuevas composiciones detergentes
MX9604019A (es) Derivados de biotina.
SE9002096D0 (sv) A method, bath and cell for the electrodeposition of tin-bismuth alloys
GB1447827A (en) Benzimidazole derivatives
ATE34983T1 (de) Indolderivate.
DK1214323T3 (da) Indoloazepiner som vasopressinreceptorantagonister
GB1470747A (en) Pyridazine derivative
EP0266006A3 (en) Novel hypotensive diuretic peptides
RO91712B1 (ro) Solutie injectabila cu actiune coronarodilatoare si antihipertensiva
SE9704503D0 (sv) Förafrande vid sköljning
UA25289C2 (uk) Спосіб приготування горілки "імператорська"
UA26426A (uk) Піридил-або піримідилвмісhі похідhі піперазиhу або 1,4-діазациклогептаhу, або їх фармакологічhо активhі кислотhо-адитивhі солі, що мають психотропhу дію
RU92004387A (ru) Триаргинининсулины

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 478797

Country of ref document: ES